Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05966324 · ClinicalTrials.gov registry record · Phase 1
Baxdrostat Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in a Japanese Population
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
NCT05966324 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 41 participants.
The verdict
NCT05966324, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
Study Summary
The goal of this study is to compare the characteristics of baxdrostat (CIN-107) in terms of baxdrostat levels over time in the blood in healthy Japanese and Caucasian volunteer participants.
Interventions
- DRUG baxdrostat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2022-07-05 |
| Est. Completion | 2022-09-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05966324
The ClinicalTrials.gov registry entry for NCT05966324 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which baxdrostat is the first listed.
NCT05966324 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05966324 about?
NCT05966324 is a clinical study titled "Baxdrostat Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in a Japanese Population". The goal of this study is to compare the characteristics of baxdrostat (CIN-107) in terms of baxdrostat levels over time in the blood in healthy Japanese and Caucasian volunteer participants.
What is the current status of trial NCT05966324?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2022-07-05. Estimated completion is 2022-09-20.
What interventions are being tested in trial NCT05966324?
The interventions under investigation include: baxdrostat (DRUG).
Who is sponsoring clinical trial NCT05966324?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.